Our study revealed a decreased frequency of the CYP2R1 rs2060793 (G > A) minor allele in patients with metastatic disease (OR 0.61, 95% CI 0.40–0.93), which suggests a protective effect of this SNP against more advanced disease. Here, CYP2R1 is linked to metastatic neoplasm.